The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension

The Effect of Eprosartan in Patients With Essential Hypertension on Renal Tubular Function and Vasoactive Hormones During Baseline Conditions and After Activation of the Sympathetic Nervous System.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00438945

Enrollment

Registered

2007-02-22

Start date

2007-01-31

Completion date

2008-01-31

Last updated

2008-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Brief summary

We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in patients with essential hypertension - during baseline conditions and after activation of the sympathetic nervous system.

Interventions

DRUGEprosartan

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age 18 - 65 years. * Body mass index less or equal to 30 kg/m2. * Women must use oral hormonal anticonceptive drugs, use intrauterine anticonceptive device, be sterilized / hysterectomized or be postmenopausal. * Arterial hypertension, defined by 24 hour ambulatory blood pressure above 125 mmHg systolic or above 80 mmHg diastolic.

Exclusion criteria

* History of myocardial infarction. * History of stroke. * Heart failure. * Endocrine organ disease. * Lung disease. * Clinically significant abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine (under 200 µmol/L will be accepted), P-albumin, p-bilirubin, p-alaninaminotransferase, P-alkaline phosphatase, p-cholesterol and B-glucose. * Clinically significant abnormal screening of the urine regarding: albumin and glucose (protein excretion below 0.5 g/L will be accepted). * Renovascular hypertension. * Malignant disease. * Alcohol abuse. * Usage of medical drugs besides antihypertensives or statins. * Drug abuse. * Pregnancy or breast feeding. * Known intolerance or allergic to eprosartan or sodium nitroprusside. * Blood donation within 1 month of the start of the study.

Design outcomes

Primary

Measure	Time frame
Heart rate	—
Fractional sodium excretion	—
Plasma levels of noradrenaline	—

Secondary

Measure	Time frame
free water clearance	—
Fractional lithium excretion	—
urinary excretion of aquaporin 2	—
Glomerular filtration rate	—
plasma levels of renin, angiotensin II, aldosterone, vasopressin, atrial natriuretic peptide and brain natriuretic peptide	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026